Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as PH-797804 material sparing tablet
PH-797804 material sparing · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Sequence 1 | EXPERIMENTAL | - |
| Sequence 2 | EXPERIMENTAL | - |
| Sequence 3 | EXPERIMENTAL | - |
| Sequence 4 | EXPERIMENTAL | - |
| Sequence 5 | EXPERIMENTAL | oral, 6mg, single dose |
| Sequence 6 | EXPERIMENTAL | oral, 6mg, single dose |
| Name | Type | Description |
|---|---|---|
| PH-797804 material sparing tablet | DRUG | oral, 6mg, single dose |
| PH-797804 Phase2b/3 with sodium lauryl sulphate | DRUG | oral, 6mg, single dose |
| PH-797804 Phase2b/3 without sodium lauryl sulphate | DRUG | oral, 6mg, single dose |
Inclusion Criteria: * Healthy male and female subjects of non-childbearing potential between the ages of 21 and 55. * No evidence of active or latent TB. * An informed consent document signed and dated by the subject. Exclusion Criteria: * Evidence, including abnormal clinical laboratory paramete...
PH-797804 material sparing is a small molecule drug candidate developed by Pfizer, Inc. (NYSE: PFE). It is a material sparing tablet formulation of PH-797804 that was evaluated in a Phase 1 clinical trial. The drug is investigational and has not been approved for any indication.
PH-797804 material sparing targets MAPK14, also known as p38 alpha mitogen-activated protein kinase. It acts as an inhibitor of this enzyme. The molecular target is MAPK14, and the compound is classified as a kinase inhibitor.
PH-797804 material sparing is developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker symbol PFE. Pfizer is the sponsor of the clinical trial involving this drug candidate.
PH-797804 material sparing is in Phase 1 clinical development. It has completed one Phase 1 trial and is not currently active in any trials. The drug remains investigational and has not been approved by the FDA for any indication.
PH-797804 material sparing has been studied in one completed Phase 1 trial, NCT01226693. The trial was titled "A Study In Healthy Volunteers To Assess The Safety, Tolerability, And Relative Oral Bioavailability Of Three Formulations Of PH-797804." It enrolled 18 healthy volunteers in Singapore and was completed.
Yes, PH-797804 material sparing is also known as PH-797804 material sparing tablet. Both names refer to the same drug candidate developed by Pfizer. The material sparing tablet is a specific formulation of PH-797804.